AAVXF:OTCMKTS
Abivax SA
139,00 US$
0,00%
(0,00) 1D
9 ივლ, 09:30:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AAVXF...
Mkt. cap
6,98 მლრდ.
Avg. vol.
0,00
Volume
0,00
52-wk high
139,00 US$
52-wk low
71,26 US$
Beta
3,09
Shares outstanding
87,53 მლნ.
No. of employees
98
Mkt. cap
6,98 მლრდ.
Avg. vol.
0,00
Volume
0,00
52-wk high
139,00 US$
52-wk low
71,26 US$
Beta
3,09
Shares outstanding
87,53 მლნ.
No. of employees
98
News stories
From web sources and news partners
Idéal Investisseur
·
1 დღის წინ
Abivax stock breaks below its 77.10 € support level despite Goldman Sachs buying recommendation
https://www.dars.gov.et/
·
4 დღის წინ
ABVX Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Keeps Spending on Pipeline
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOმარკ დე გარიდელი | ჰარტმუტ ჯეი ერლიხი
Employees98
Founded4 დეკ. 2013
Headquarters-
Sector-
Websiteabivax.com